Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Rapid Readouts: A Global Study of Advanced Dosimetry in the Treatment of HCC With Y 90 Glass Microspheres

May 12th 2021

Riad Salem, MD, presents slides supporting global real-world data confirming a significant association between tumor-absorbed dose, objective response between tumor-absorbed dose and overall survival in patients with hepatocellular carcinoma (HCC) treated with yttrium-90 glass microspheres.

Dr. Janjigian on the FDA Approval of Nivolumab Plus Chemotherapy in Frontline Gastric Cancer

May 11th 2021

Yelena Y. Janjigian, MD, discusses the FDA approval of nivolumab plus chemotherapy in frontline gastric cancer.

Dr. Patel on Selecting Patients for Treatment With Atezolizumab/Bevacizumab in HCC

May 11th 2021

Monica A. Patel, MD, discusses factors that determine whether a patient with hepatocellular carcinoma is a good candidate to receive a combination of atezolizumab and bevacizumab.

FDA Grants Orphan Drug Designation to BOLD-100 for Gastric Cancer

May 11th 2021

The FDA has granted an orphan drug designation to the first-in-class ruthenium-based small molecule therapeutic BOLD-100 for the treatment of patients with gastric cancer.

Multidisciplinary Care Is Paramount as New Therapies Emerge in Metastatic Pancreatic Cancer

May 6th 2021

Although the standard-of-care treatment for patients with metastatic pancreatic cancer remains largely unchanged with multi-agent chemotherapy, the role for multidisciplinary care has expanded significantly in recent years.

The Future of Cancer Immunotherapy Lies in Combinational Approaches

May 6th 2021

Arsen Osipov, MD, discusses the potential for ongoing research with immunotherapeutic approaches in gastrointestinal malignancies, including CAR T-cell therapy, bispecific T-cell engagers, and vaccines.

Dr. Lee on Selecting a Treatment Approach for Neuroendocrine Tumors

May 6th 2021

Yoomi Lee, MD, discusses her process for selecting a treatment approach for patients with neuroendocrine tumors.

Dr. Uboha on Early Efficacy Data With Zanidatamab in HER2+ Upper GI Cancers

May 5th 2021

Nataliya V. Uboha, MD, PhD, discusses early efficacy data demonstrated with zanidatamab in HER2-expressing upper gastrointestinal cancers.

FDA Approves Pembrolizumab for HER2+ Gastric Cancer

May 5th 2021

The FDA has approved pembrolizumab for use in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma.

FDA Grants Priority Review to Ivosidenib in IDH1-Mutant Cholangiocarcinoma

May 5th 2021

The FDA has granted a priority review to the supplemental new drug application for ivosidenib tablets as a treatment option for patients with previously treated, IDH1-mutant cholangiocarcinoma.

Rolling Submission Completed for Surufatinib in Advanced Neuroendocrine Tumors

May 3rd 2021

The rolling submission of a new drug application to the FDA for surufatinib for the treatment of patients with pancreatic and non-pancreatic neuroendocrine tumors has been completed.

Dr. Jones on Future Research Efforts in Pancreatic Cancer

May 3rd 2021

Amy Jones, MD, discusses future research efforts in pancreatic cancer.

Trastuzumab Deruxtecan Under Investigation in HER2+ CRC in DESTINY-CRC02 Trial

May 3rd 2021

The first patient has received treatment with fam-trastuzumab deruxtecan-nxki in the phase 2 DESTINY-CRC02 trial, which is exploring the safety and efficacy of the antibody-drug conjugate in patients with HER2-overexpressing, BRAF wild-type, RAS-mutant or wild-type or mutant locally advanced, unresectable or metastatic colorectal cancer who have progressed following treatment with standard chemotherapy.

Dr. Kim on the FDA Approval of TheraSphere Y-90 Glass Microspheres in HCC

April 30th 2021

Edward Kim, MD, discusses the FDA approval of TheraSphere™ Yttrium-90 Glass Microspheres in hepatocellular carcinoma.

FDA Panel Opposes Nivolumab for Second-line Advanced HCC

April 29th 2021

In a 5 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee voted to oppose maintaining the accelerated approval of nivolumab monotherapy for patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib.

Riedel and Van Tine Spotlight Sarcoma Advances and Preview Ongoing Studies

April 29th 2021

Dr. Riedel and Dr. Van Tine discuss the multidisciplinary management of patients with sarcoma, the clinical impact of the FDA approval of ripretinib in the gastrointestinal stromal tumor paradigm, and other exciting advances in sarcoma.

ODAC Unanimously Backs Pembrolizumab for Second-line Advanced HCC

April 29th 2021

In an 8 to 0 vote, the FDA’s Oncologic Drugs Advisory Committee voted to support the accelerated approval of pembrolizumab monotherapy for patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib.

ODAC Votes Against Pembrolizumab for PD-L1+ Gastric/GEJ Cancer

April 29th 2021

In a 6 to 2 vote, the FDA’s Oncologic Drugs Advisory Committee voted against maintaining the accelerated approval of pembrolizumab for the treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have received 2 or more lines of therapy.

Atezolizumab/Bevacizumab Combo Sets the Standard for New Doublets in Advanced HCC

April 29th 2021

The combination of atezolizumab and bevacizumab has become the frontline standard of care for most patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

Amgen Acquires Five Prime for its Oncology Pipeline

April 28th 2021

Amgen has completed its planned acquisition of Five Prime Therapeutics for $38.00 per share in cash, or approximately $1.9 billion.